



For Immediate Release

Dr. David Granville, viDA CSO, to Present at Society for Leukocyte Biology 50th Annual Meeting

Vancouver, British Columbia, Canada, October 2, 2017 -- viDA Therapeutics, Inc. (viDA), a late pre-clinical stage biotechnology company advancing first-in-class drugs based on inhibitors of the extracellular serine protease, Granzyme B, to treat autoimmune and chronic inflammatory age-related diseases, announced today that Dr. David Granville will present at the 50th annual meeting of the **Society for Leukocyte Biology** in Vancouver, British Columbia on **Wednesday, October 4, 2017**.

His presentation, entitled “**Granzyme B in Aging and Impaired Collagen Remodeling**” is part of the Aging, Inflammation and Fibrosis Satellite Symposium, sponsored by the National Institutes on Aging (NIA). The NIA leads the US federal government effort conducting and supporting research on aging and the health and well-being of older people. The Institute’s broad scientific program seeks to understand the nature of aging and to extend the healthy, active years of life.

About viDA, Discoid Lupus Erythematosus (DLE) and VTI-1002

viDA Therapeutics, Inc. (viDA), a Vancouver, Canada based privately held biotechnology company, is focused on developing first-in-class therapies for treating autoimmune and chronic inflammatory diseases with high unmet need, including orphan products. The lead product candidate, VTI-1002, is in a topical formulation for the treatment of the autoimmune skin condition, DLE. This disease is a severe chronic dermatological disease having a significant impact on quality of life due to severe facial disfigurement and scars. For additional information about viDA, please visit www.vidatherapeutics.com.

Media Contact:

Alistair Duncan, B.Sc., C.A.

President & CEO

Phone: (604)762-4789

aduncan@vidatherapeutics.com

Media Contact:

Alistair Duncan, B.Sc., C.A.

President & CEO

Phone: (604)762-4789

aduncan@vidatherapeutics.com